neoadjuvant chemotherapy and CCRT

Phase 3Small molecule

neoadjuvant chemotherapy and CCRT is one of 46 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Hypopharyngeal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Hypopharyngeal CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

34 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

79 3

Beyfortus

BeiGene

Phase 3

6 4

Taxotere

AAvyxa

Phase 3

16 5

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

6 7

Paraplatin

AAvyxa

Phase 3

4 8

Adrucil

EElorac, Inc.

Phase 3

3 9

Decadron

AAspen Global Incorporated

Phase 3

1 10

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT05772208

Q2 2031

Phase 3Not yet recruiting

Hypopharyngeal Carcinoma

NCT06957938

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting·FFudan University·Phase 3·NCT05772208·459 enrolled

Hypopharyngeal Carcinoma1 trial

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Not yet recruiting·FFudan University·Phase 3·NCT06957938·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for neoadjuvant chemotherapy and CCRT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neoadjuvant chemotherapy and CCRT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neoadjuvant chemotherapy and CCRT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

neoadjuvant chemotherapy and CCRT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2031

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

Hypopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News